2083eTiP A phase II study of ateganosine (THIO; 6-thio-2'-deoxyguanosine) in combination with immune checkpoint inhibitor (ICI) in patients with advanced non-small cell lung cancer (NSCLC) resistant to prior ICI and chemotherapy: THIO-101 trial in progress